Results 221 to 230 of about 97,723 (266)

Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα). [PDF]

J Med Chem
Rej RK, Hu B, Chen Z, Acharyya RK, Wu D, Metwally H, McEachern D, Wang Y, Jiang W, Bai L, Nishimura LS, Gersch CL, Wang M, Wen B, Sun D, Carlson K, Katzenellenbogen JA, Xu G, Zhang W, Wu W, Priestley ES, Sui Z, Rae JM, Wang S.   +23 more
europepmc   +1 more source

The Endocrine Disrupting Compounds Bisphenol‐A and α‐Zeranol Mimic the Estrogen Transcriptional Program to Promote Proliferation and Stemness in Breast Cancer Cells

Molecular Carcinogenesis, EarlyView.
ABSTRACT Excessive activation of the estrogen receptor (ER) drives proliferation, progression, and the formation of breast cancer stem cells (CSCs) in ER‐positive breast cancer. Estrogenic endocrine disrupting compounds (EDCs) found in plastics, water, and food are also able to bind to the ER.
Cassandra Winz, Eric Li, Caroline Xie, Kyo Chang Lee, Kevin Boguszewski, Shlok Rohatagi, Rita Hahn, Ray Rancourt, Philip Furmanski, Nanjoo Suh   +9 more
wiley   +1 more source

Aptamer Proteolysis-Targeting Chimeras (PROTACs): A Novel Strategy to Combat Drug Resistance in Estrogen Receptor α-Positive Breast Cancer. [PDF]

ACS Pharmacol Transl Sci
Feng Y, Zhang Z, Zhang H, Guo H, Tan C, Xu N, Tan Y, Jiang Y.   +7 more
europepmc   +1 more source

Exocrine Gland Dysfunction in Parkinson's Disease: Pathophysiology, Clinical Manifestations, and Therapeutic Perspectives—A Narrative Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz, Marina Farah, Laura Silveira‐Moriyama   +2 more
wiley   +1 more source

Asymmetric allostery in estrogen receptor-α homodimers drives responses to the ensemble of estrogens in the hormonal milieu. [PDF]

Proc Natl Acad Sci U S A
Min CK, Nwachukwu JC, Hou Y, Russo RJ, Papa A, Min J, Peng R, Kim SH, Ziegler Y, Rangarajan ES, Izard T, Katzenellenbogen BS, Katzenellenbogen JA, Nettles KW.   +13 more
europepmc   +1 more source

Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is a worldwide, complex neurodegenerative disorder influenced by both genetic and environmental factors. Around 15–20% of PD cases are linked to genetic mutations, providing insights into the disease's pathogenesis.
Chiara Meneghini, Luca Gallo, Arianna Sala, Enza Maria Valente, Micol Avenali, Silvia Paola Caminiti   +5 more
wiley   +1 more source

An estrogen receptor α-derived peptide improves glucose homeostasis during obesity. [PDF]

Nat Commun
Yang W, Jiang W, Liao W, Yan H, Ai W, Pan Q, Brashear WA, Xu Y, He L, Guo S.   +9 more
europepmc   +1 more source

Ferroptosis and Its Emerging Role in Gestational Diabetes Mellitus

Medicine Advances, EarlyView.
Ferroptosis contributes to the development of gestational diabetes mellitus (GDM) through iron overload, lipid peroxidation, and antioxidant system disruption. These changes impair adipocyte and β‐cell function, promoting insulin resistance and hyperglycemia.
Jinfeng Xu, Yuan Tian, Hongbin Zhu, Bing Peng, Chunheng Mo   +4 more
wiley   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

Obesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu, Hao Dai, Huilin Tang, William T. Donahoo, Thomas J. George, Ramon C. Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D. Licht, John M. Allen, Kelvin P. Lee, Jingchuan Guo, Jiang Bian   +13 more
wiley   +1 more source

LINC00173 silence and estrone supply suppress ER⁺ breast cancer by estrogen receptor α degradation and LITAF activation. [PDF]

Cancer Sci
Xie Y, Shan M, Yu J, Du Y, Wu C, Liu S, Li J, Xiao Y, Yan Y, Li N, Qin J, Lan L, Wang Y.   +12 more
europepmc   +1 more source